A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Fairtility Expands European Market Penetration with CHLOE EQ ™, as Clinics in Five Countries Embrace Breakthrough AI Technology in IVF

One Year Following CE MDR Clearance, Fairtility has emerged as the AI Decision Support Platform of Choice in European Fertility Practice

Fairtility, the transparent AI innovator powering in vitro fertilization (IVF) for improved outcomes, announced today its expanding geographic footprint across Europe. One year since receiving CE MDR clearance for CHLOE EQ™, Fairtility has established a strong presence in countries, including the United Kingdom, Spain, Turkey, Greece, and Norway, in its mission to transform the IVF landscape.

“Clinics across Europe have embraced CHLOE EQ™, and they are seeing the disruptive capabilities of the platform, both in terms of embryo selection and providing patients the most advanced and transparent IVF experience available,” said Eran Eshed, CEO and Co-founder of Fairtility. “These clinics are charting the path forward as AI progresses to become part of the standard of care across the IVF journey.”

Fairtility has implemented its transparent AI tool in 10 clinics, including:

With 1 in 6 people experiencing infertility in their reproductive years, the IVF market is growing.  Fertility care providers must expand capacity by seeking opportunities to create workflow efficiencies both within and beyond the embryology lab. CHLOE EQ™ represents a breakthrough in the IVF field, enabling clinics to reduce time spent on manual embryo annotation by an average of 33 percent per cycle. This has resulted in a 30-50 percent increase in IVF cycle capacity in clinics.

“Implementing AI technologies entering the IVF space challenges traditional norms and drives innovation forward for the entire industry,” said Suzanne Cawood, Director of Embryology, CRGH UK. “AI tools like CHLOE EQ™ are necessary for improving the efficiency of IVF processes and increasing transparency. They are also the answer to IVF professional shortages and embryologist burnout resulting from the volume of administration associated with a single IVF cycle. Fairtility’s AI makes IVF more efficient and accessible to the growing population of people seeking fertility treatment.”

To thrive in the digital age, clinics must embrace a fully digital IVF journey that is streamlined and transparent for all stakeholders. Fairtility understands this imperative and is supporting clinics in achieving digital transformation for the IVF journey. CHLOE EQ™integrates with leading IVF EMR providers, enabling data to flow freely from lab-to-fertility specialist-to-patient, paving the path for more open communication on treatment plans and progress.

“We selected CHLOE EQ because of its ability to provide quantifiable biological data on embryo development, quality and viability. This transparency and interpretability set it apart from other AI-based decision support tools available,” said Shabana Sayed, Senior Embryologist and IVF Lab Manager at Klinikk Hausken, part of Medicover. “Our embryologists see this system as a companion that helps augment and standardize decision making. It speaks to them in a language they understand –human biology.”

CHLOE EQ™ is the only commercial AI decision support platform able to quantify biomarkers throughout embryo development, automatically analyzing established morphological and morphokinetic features, which are traditionally captured in a time-consuming and subjective manner. Through translation of computational information to biologically relevant interpretation made ready for clinical decision making, CHLOE is the first and only transparent AI system able to automate analysis of the full spectrum of biological events related to embryo development.

“Together with our visionary partner clinics, we are reshaping the fertility landscape, addressing the urgent need for improved outcomes, and providing patients with the transparency and control they desire,” said Eshed.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy